Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleCLINICAL INVESTIGATIONS

18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease

Axel Rominger, Tobias Saam, Sarah Wolpers, Clemens C. Cyran, Michael Schmidt, Stefan Foerster, Konstantin Nikolaou, Maximilian F. Reiser, Peter Bartenstein and Marcus Hacker
Journal of Nuclear Medicine October 2009, 50 (10) 1611-1620; DOI: https://doi.org/10.2967/jnumed.109.065151
Axel Rominger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Saam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Wolpers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens C. Cyran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Schmidt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Foerster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konstantin Nikolaou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maximilian F. Reiser
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bartenstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus Hacker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1. 

    PET/CT image analysis. (A) Example of modified calcified plaque scoring system (16). Images from left to right show scores of 0 (no calcified plaque), 1 (calcified plaque involving <10% of vessel circumference), 2 (calcified plaque involving 10%−25%), 3 (calcified plaque involving 25%−50%), and 4 (calcified plaque involving >50%). (B) Example of TBR calculation method. ROIs were drawn in center of vena cava inferior (red) and in arterial wall of abdominal aorta (black). ABA = abdominal aorta; CP = calcified plaque.

  • FIGURE 2. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2. 

    Arterial 18F-FDG uptake and calcifications in relation to patient outcome. From left to right are representative transaxial CT, 18F-FDG PET, and fused PET/CT images. (A) 81-y-old man with significantly increased uptake in region of aortic arch (TBR, 1.78; mean TBR, 1.62). Calcified plaque in aortic arch was 3, and calcified plaque sum was 21. Patient experienced myocardial infarction 14 mo later. (B) 45-y-old man with calcified plaque score of 0 in aortic arch (calcified plaque sum, 2) but aortic arch TBR of 1.90 (mean TBR, 1.74), who experienced vascular event 14 mo after PET/CT. (C) 64-y-old woman with calcified plaque score of 4 in abdominal aorta (calcified plaque sum, 14) and TBR of 1.49 in abdominal aorta (mean TBR, 1.56), who experienced no vascular event during follow-up.

  • FIGURE 3. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3. 

    Kaplan–Meier cumulative event-free survival curves: mean TBR using mean TBR cutoff of ≥1.7 (A), calcified plaque sum using calcified plaque sum cutoff of ≥15 (B), and combined subgroups of mean TBR and calcified plaque sum (C). *P < 0.01. **P < 0.001.

  • FIGURE 4. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4. 

    Distribution of arterial segments with different patterns of 18F-FDG uptake and calcifications in patients with and without vascular event during follow-up: proportional and disproportional distribution patterns in event group vs. control group (A); arterial segments with high TBR and low calcified plaque values vs. segments with low TBR and high calcified plaque values (B).

Tables

  • Figures
    • View popup
    TABLE 1

    Baseline Characteristics of Study Population

    ParameterControl group (n = 319)Event group (n = 15)P
    Median age (y)59.0 (48.0, 66.0)66.0 (55.0, 71.5)<0.05
    Men (n)123 (38.6%)10 (66.7%)<0.05
    Body mass index25.2 ± 4.6 (15.0, 48.0)25.8 ± 5.6 (17.0, 35.0)NS
    Median follow-up time (mo)30.0 (20.0, 36.0)27.0 (21.0, 33.0)NS
    Events (n)15
     Cardiac10
     Cerebral5
    Cardiovascular risk factors (n)
     Hypercholesterolemia57 (17.9%)3 (20%)NS
     Hypertension60 (18.8%)11 (73.3%)<0.05
     Smoker30 (9.4%)4 (26.7%)NS
     Diabetes mellitus15 (4.7%)1 (6.7%)NS
     Family history of cardiovascular disease76 (25.2%)5 (33.3%)NS
     Mean calcified plaque sum4.6 ± 5.6 (0, 30)10.9 ± 8.3 (0, 23)<0.05
     Mean TBR1.3 ± 0.2 (0.8, 2.0)1.9 ± 0.6 (1.4, 3.9)<0.05
    Therapy (n)
     Current statin medication14 (4.4%)1 (6.7%)NS
     Ongoing chemotherapy43 (13.5%)2 (13.3%)NS
    • NS = not statistically significant.

    • Values are mean ± SD followed by range, median followed by (Q1, Q3), or number followed by percentage.

    • View popup
    TABLE 2

    Correlation of Baseline Characteristics with Mean TBR and Calcified Plaque Sum

    ParameterAgeFuture eventMale sexHypertensionSmokingDiabetesHypercholesterolemiaMean TBRCalcified plaque sum
    Mean TBR0.234*0.393*0.109†0.190*NSNSNS1.000
    Calcified plaque sum0.496*0.224*0.226*0.288*0.166*0.213*NS0.187*1.000
    • ↵* P < 0.01.

    • ↵† P < 0.05.

    • NS = not statistically significant.

    • Data are Pearson correlation coefficients.

    • View popup
    TABLE 3

    Cox Proportional Hazards Model

    Future cerebrovascular or cardiovascular event
    Univariate analysisMultivariate analysis
    ParameterHR95% CIPHR95% CIP
    Age (≥65 y)2.1810.790–6.0230.132NS
    Sex (M)3.3551.144–9.8040.027NS
    Cardiovascular risk factor (+)*12.1301.595–92.2380.0168.7111.126–67.3860.038
    Calcified plaque sum (≥15)9.2003.232–26.192<0.00013.5601.171–10.8210.025
    Mean TBR (≥1.7)20.2917.214–57.071<0.000114.1444.823–41.482<0.0001
    • ↵* Minimum of 1 cardiovascular risk factor present, such as family history, hypercholesterolemia, diabetes, hypertension, or smoking.

    • HR = hazard ratio; CI = confidence interval; NS = not statistically significant.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 50 (10)
Journal of Nuclear Medicine
Vol. 50, Issue 10
October 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease
Axel Rominger, Tobias Saam, Sarah Wolpers, Clemens C. Cyran, Michael Schmidt, Stefan Foerster, Konstantin Nikolaou, Maximilian F. Reiser, Peter Bartenstein, Marcus Hacker
Journal of Nuclear Medicine Oct 2009, 50 (10) 1611-1620; DOI: 10.2967/jnumed.109.065151

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease
Axel Rominger, Tobias Saam, Sarah Wolpers, Clemens C. Cyran, Michael Schmidt, Stefan Foerster, Konstantin Nikolaou, Maximilian F. Reiser, Peter Bartenstein, Marcus Hacker
Journal of Nuclear Medicine Oct 2009, 50 (10) 1611-1620; DOI: 10.2967/jnumed.109.065151
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Continuous positive airway pressure but not Liraglutide-mediated weight loss improves early cardiovascular disease in obstructive sleep apnea: Data from a randomized proof-of-concept study
  • Vascular Inflammation in Subclinical Atherosclerosis Detected by Hybrid PET/MRI
  • Unraveling Vascular Inflammation: From Immunology to Imaging
  • Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by 18F-Fluoride and 18F-FDG
  • Head-to-Head Comparison of Inflammation and Neovascularization in Human Carotid Plaques: Implications for the Imaging of Vulnerable Plaques
  • Arterial and Cellular Inflammation in Patients with CKD
  • Positron Emission Tomography Assessment of Left Main Coronary Arterial Inflammation With Coronary Computed Tomographic Angiography Validation Before and After Statin Therapy: More Promise for Fluorodeoxyglucose Vascular Uptake?
  • Coronary Plaque Morphology and the Anti-Inflammatory Impact of Atorvastatin: A Multicenter 18F-Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Study
  • GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis
  • Evaluation of 68Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization
  • Thresholds for Arterial Wall Inflammation Quantified by 18F-FDG PET Imaging: Implications for Vascular Interventional Studies
  • GM-CSF Enhances Macrophage Glycolytic Activity In Vitro and Improves Detection of Inflammation In Vivo
  • Arterial Stiffness Is Positively Associated With 18F-fluorodeoxyglucose Positron Emission Tomography-Assessed Subclinical Vascular Inflammation in People With Early Type 2 Diabetes
  • Relationship Between Measures of Adiposity, Arterial Inflammation, and Subsequent Cardiovascular Events
  • Radiotracer Imaging of Peripheral Vascular Disease
  • Systemic Atherosclerotic Inflammation Following Acute Myocardial Infarction: Myocardial Infarction Begets Myocardial Infarction
  • Carotid FDG Uptake Improves Prediction of Future Cardiovascular Events in Asymptomatic Individuals
  • Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation in Familial Hypercholesterolemia
  • A Randomized Trial on the Optimization of 18F-FDG Myocardial Uptake Suppression: Implications for Vulnerable Coronary Plaque Imaging
  • Oxidized Low-Density Lipoprotein Stimulates Macrophage 18F-FDG Uptake via Hypoxia-Inducible Factor-1{alpha} Activation Through Nox2-Dependent Reactive Oxygen Species Generation
  • Molecular imaging of atherosclerosis: clinical state-of-the-art
  • Is Carotid Intima-Media Thickness as Predictive as Other Noninvasive Techniques for the Detection of Coronary Artery Disease?
  • Imaging and Nanomedicine in Inflammatory Atherosclerosis
  • Measurement of Arterial Activity on Routine FDG PET/CT Images Improves Prediction of Risk of Future CV Events
  • 18F-FDG Imaging of Carotid Arteries for Identifying the Vulnerable Patient: Are We at the Beginning of the End?
  • Radiotracer Imaging of Peripheral Vascular Disease
  • Imaging of Arterial Inflammation: Keeping Our Cool on a Hot Topic
  • Relation of Carotid Artery 18F-FDG Uptake to C-Reactive Protein and Framingham Risk Score in a Large Cohort of Asymptomatic Adults
  • Bioenergetic Profiles Diverge During Macrophage Polarization: Implications for the Interpretation of 18F-FDG PET Imaging of Atherosclerosis
  • Focal Arterial Inflammation Precedes Subsequent Calcification in the Same Location: A Longitudinal FDG-PET/CT Study
  • Subclinical Vasculitis as a Potential Mechanism to Explain the Heightened Cardiovascular Risk in Rheumatoid Arthritis
  • Impact of Noninsulin-Dependent Type 2 Diabetes on Carotid Wall 18F-Fluorodeoxyglucose Positron Emission Tomography Uptake
  • Feasibility of 11C-Acetate PET/CT for Imaging of Fatty Acid Synthesis in the Atherosclerotic Vessel Wall
  • Prevalence and Risk Factors of Carotid Vessel Wall Inflammation in Coronary Artery Disease Patients: FDG-PET and CT Imaging Study
  • Imaging Inflammatory Changes in Atherosclerosis: Multimodal Imaging Hitting Stride
  • Incidental Diagnosis of Thrombus Within an Aneurysm on 18F-FDG PET/CT: Frequency in 926 Patients
  • Imaging Atherosclerosis With F18-Fluorodeoxyglucose Positron Emission Tomography: What Are We Actually Seeing?
  • Correlation of Inflammation Assessed by 18F-FDG PET, Active Mineral Deposition Assessed by 18F-Fluoride PET, and Vascular Calcification in Atherosclerotic Plaque: A Dual-Tracer PET/CT Study
  • Vessel Wall Inflammation in Spontaneous Cervical Artery Dissection: A Prospective, Observational Positron Emission Tomography, Computed Tomography, and Magnetic Resonance Imaging Study
  • Imaging the Vulnerable Plaque
  • Association of Adiponectin, Resistin, and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography
  • In Vivo Imaging of Mineral Deposition in Carotid Plaque Using 18F-Sodium Fluoride PET/CT: Correlation with Atherogenic Risk Factors
  • The Year in Molecular Imaging
  • Imaging Atherosclerotic Plaque Inflammation by Fluorodeoxyglucose With Positron Emission Tomography: Ready for Prime Time?
  • The Role of 18F-FDG PET in Aortic Dissection
  • In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire